EU

摘要： 采用浸渍法合成了TODGA-JZC树脂并进行表征,研究了接触时间、硝酸浓度、金属离子杂质含量等对TODGA-JZC、TODGA-JZF树脂吸附Am(Ⅲ)的影响以及Eu静态容量。结果表明:两种TODGA树脂均具有较好的耐酸性;两种树脂对^(241)Am吸附分配比随接触时间的增加而升高,60 min趋于平衡;Fe等金属离子杂质(0~20 g/L)对241Am的吸附分配比影响较小;随着硝酸浓度的升高,241Am的吸附分配比增加,4 mol/L硝酸时TODGA-JZC和TODGA-JZF树脂对^(241)Am的吸附分配比分别为6.8×10^(4)和1.2×10^(5)mL/g;在4 mol/L HNO_(3)、1 mg/mL Eu体系中,TODGA-JZC、TODGA-JZF树脂对Eu的静态容量分别为18 mg/mL、9 mg/mL。

摘要： Arguably,globalisation has caused an identity crisis in Europe.As national borders became more integrated in the last few decades,the volume of migrants into the EU and the value of ethnicity held by Europeans have also been on the rise.Particularly,the bloc has been facing an influx of immigrants from the African and Middle East continents.As for the EU leaders,their stance on a common migration policy is entrenched in the wider social,cultural,and political processes that depict an endangered European identity.This would explain the current debate on immigration in many of the European countries appears to have been securitised.This paper takes a wider look into how immigration has reshaped the EU,as well as,how EU immigrants have had to shift their identities as they struggle to fit into their new society.

摘要： Objective To analyze the current situation of research and application of drug regulatory science in EU,and provide suggestions for policy-making of drug regulatory in China.Methods The policy guidelines issued by European Medicines Agency(EMA)and domestic and foreign literature were retrieved to summarize how to carry out drug regulation science in Europe.Results and Conclusion A strategic plan was formulated by the EMA for the implementation of drug regulatory science,and the construction of academic system and discourse system of regulatory science were improved,which played a role in promoting the progress of European drug regulatory science.It is suggested that a phased strategic plan of regulatory science should be established to clarify strategic objectives and main tasks in China as soon as possible.Besides,the construction of discipline system and discourse system should be strengthened to realize the scientific supervision of drugs.

摘要： 针对用户出行新需求,“中国汽车定制专家”上汽大通MAXUS于上海五五购车节,焕新上市了高颜值大五座新能源SUV 2021款EUNIQ 6(简称E6)。EUNIQ 6纯电车型LITE乐享版售价16.28万元、LITE+智享版售价17.28万元、MATE潮享版售价18.28万元、EXTRA尊享版售价20.28万元。

摘要： 根据实际业务模型进行信息安全配置优化,通过分析不同网络出口节点部署下的信息安全应用场景,减少服务器、存储等硬件资源的投入,以更好地维护网络安全,提高数据中心建设的经济效益,推动数据中心的绿色节能发展。

摘要： Objective To provide references and suggestions for the application of real-world evidence in the decision-making of drug regulation in China.Methods The application of EU real-world evidence in drug regulatory decision support was analyzed through literature research and other methods,and the specific operation of its application was demonstrated by case studies.Results and Conclusion The application of EU real-world evidence in drug regulatory decision-making has achieved certain results and is in a stable development stage.The application of real-world evidence in China’s drug regulation is feasible.The successful application of EU real-world evidence can provide reference for China.

摘要： Objective To analyze the value of EU real-world evidence(RWE)in supporting the expanded indications for drugs and to provide reference for the decision-making of expanding drug indications supported by RWE in China.Methods By searching relevant domestic and foreign literature and case analysis,the practice of the RWE of EU to support the expansion indications for drugs was investigated.Results and Conclusion The EU uses RWE to carry out adaptive path research,which provides a new idea for drug R&D and approval.Besides,it also provides evidence in supporting the research of expanded indications for drugs.With the increasing cognition of RWE,it will play a key role in medical and regulatory decisions in China.

摘要： Objective To analyze the research and application status of real-world evidence(RWE)in the European Union(EU)and provide a reference for China’s government.Methods By consulting the policy guidelines issued by EU EMA and the documents of European countries at home and abroad,the basic principles and case notes of EU RWE implementation were comprehensively analyzed.Results and Conclusion Research on RWE in EU is mainly carried out from four aspects:R&D decision,application of expanded trial certificate,medical insurance decision,and supervision decision,which plays an important role in the progress of European clinical medicine.Therefore,researchers in China should draw lessons from these four perspectives and design reasonable research directions and programs.

摘要： Objective To analyze the application of EU real-world evidence in the decision-making of new drug research and development(R&D),and to provide policy recommendations for China’s government to make new drug R&D decisions.Methods The relevant policy documents of the EU on the development of new drugs and other domestic and foreign literature on the real-world evidence were analyzed to obtain the role and application of the current EU real-world evidence in the implementation of new drug development policies.Results and Conclusion At present,the EU is carrying out the national synchronous scientific advisory policy,urging the formation of a European innovation framework,and providing decision-making for new drug R&D selection and program design based on real-world evidence.It is recommended that China build a real-world medical database and design a new drug screening platform to help companies,scientific research institutions assess target drugs.In addition,a national scientific advisory platform should be set up to integrate scientific research strength and provide technical support for new drug R&D institutions.

摘要： Objective To summarize the concept,background,application value of real-world evidence(RWE)and its enlightenment to China based on the analysis of the information about the RWE supporting health decision in the European Union,and to provide a reference for Chinese health departments.Methods Through literature research and data collection,the requirements of EU countries,especially some typical countries,for clinical evidence in health decision were obtained,and the application of RWE in supporting health decision in EU was analyzed with specific cases.Results and Conclusion RWE plays an increasingly important role in supplementing the evidence base of clinical trials,verifying the safety and effectiveness of medical devices,and accelerating the market access of new drugs.With the improvement of RWE quality,RWE will not only be used in the evaluation of biological agents and chemical drugs,but also play an important role in the evaluation of traditional Chinese medicine and the post-marketing evaluation of medical devices.

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 采用改进的喷雾热解法合成了发光性能优异的(Y,Gd)BO3:Eu红色荧光粉,通过调节前驱体溶液的性质改善了荧光粉产物的形貌特征以提高其物理和光学性能。结果表明,在前驱体溶液中加入氨水能够影响喷雾热解过程中液滴中颗粒生成方式,以控制产物颗粒形貌,经后续热处理后获得了无团聚的致密球形荧光粉颗粒；由X射线衍射分析可知,在1100°C下后续热处理3h可以获得结晶良好的所需纯相物质.同时也考察了激活剂浓度对(Y,Gd)BO3:Eu荧光粉体发光强度的影响；在优化的掺杂浓度下,采用氨水改性的前驱体溶液经过喷雾热解-热处理后获得荧光粉产物具有优良的发光强度。

摘要： 用微波辐射法快速合成了红色荧光化合物La2O2S:Eu。用X射线粉末衍射(XRO)、扫描电镜(SEM)、荧光分光光度计等手段对合成产物进行了分析和表征,并研究了不同助熔剂Li2C03、Na2CO3、K2CO3、(NH4)2CO3对材料物相结构、微观形貌及发光性能的影响。结果表明:4种助熔剂的加入均可得到单相晶体,材料的晶体结构为六方晶系,与La2O2S的相同。颗粒尺寸以及微观形貌因助熔剂的不同而有所差别。发光性质研究表明:不同助熔剂的加入并没有改变样品发射谱主峰位置(627nm),但对其峰强度产生明显影响;激发光谱主峰的位置及强度也发生了较大变化。

摘要： 用微波辐射法快速合成了红色荧光化合物La2O2S:Eu。用X射线粉末衍射(XRO)、扫描电镜(SEM)、荧光分光光度计等手段对合成产物进行了分析和表征,并研究了不同助熔剂Li2C03、Na2CO3、K2CO3、(NH4)2CO3对材料物相结构、微观形貌及发光性能的影响。结果表明:4种助熔剂的加入均可得到单相晶体,材料的晶体结构为六方晶系,与La2O2S的相同。颗粒尺寸以及微观形貌因助熔剂的不同而有所差别。发光性质研究表明:不同助熔剂的加入并没有改变样品发射谱主峰位置(627nm),但对其峰强度产生明显影响;激发光谱主峰的位置及强度也发生了较大变化。

摘要： 用微波辐射法快速合成了红色荧光化合物La2O2S:Eu。用X射线粉末衍射(XRO)、扫描电镜(SEM)、荧光分光光度计等手段对合成产物进行了分析和表征,并研究了不同助熔剂Li2C03、Na2CO3、K2CO3、(NH4)2CO3对材料物相结构、微观形貌及发光性能的影响。结果表明:4种助熔剂的加入均可得到单相晶体,材料的晶体结构为六方晶系,与La2O2S的相同。颗粒尺寸以及微观形貌因助熔剂的不同而有所差别。发光性质研究表明:不同助熔剂的加入并没有改变样品发射谱主峰位置(627nm),但对其峰强度产生明显影响;激发光谱主峰的位置及强度也发生了较大变化。

摘要： 本发明公开了一种Eu2+和Eu3+铕离子混合激活的荧光粉、制备方法及应用，属于发光材料技术领域。本发明提供的荧光粉其化学式为Na2‑2xEu2xAl2B4O10，其中x为铕离子掺杂摩尔数，0.001≤x≤0.07；它的基质为Na2Al2B4O10，激活剂是铕离子，是Eu2+和Eu3+共存的混合。本发明提供的荧光粉的制备采用化学溶胶‑凝胶法合成，烧结在空气气氛中进行。荧光粉在紫外和近紫外光的激发下，可以得到从蓝光到白光的不同发光颜色。本发明制备工艺简单，尤其是对于制备设备的密封性要求不高，生产安全性好，成本低廉、无污染排放，得到的荧光粉为多色发光，且颜色连续可调。

摘要： 本发明公开一种Eu2+和Eu3+共掺杂的玻璃陶瓷荧光温度探针复合材料及其制备方法和应用。该玻璃陶瓷组分如下SiO2：40mol﹪；GeO2：5mol﹪；Al2O3：25mol﹪；Ga2O3：5mol﹪；NaF：x mol﹪；YF3：y mol﹪；EuF3：z mol﹪；其中x+y+z＝25且7≤x≤18，6.9≤y≤17.9，0.1≤z≤4。上述玻璃陶瓷采用熔体急冷法和后续晶化热处理制备。本发明玻璃陶瓷在紫外光激发条件下，可同时探测到源自Eu2+蓝光和Eu3+红光的双模发射。随着温度升高，Eu2+/Eu3+荧光强度比作为测温参数，温度灵敏度最高可达2﹪K‑1。

摘要： 本发明涉及一种由无线发射/接收单元（WTRU）实施的传送增强型上行链路（EU）数据的方法及一种传送EU数据的WTRU。该方法包括：接收用于EU操作的配置参数；标识在下一个传输时间间隔（TTI）针对传输使用的HARQ进程；确定所标识的HARQ进程在所述下一个TTI针对新数据是否可用；在所标识的HARQ进程在所述下一个TTI针对新数据可用的条件下，基于MAC‑d流或逻辑信道优先级选择在增强型专用信道（E‑DCH）上进行传输的数据，设置传输状态以指示新传输，以及根据所标识的HARQ进程传送所选择的数据；在所标识的HARQ在所述下一个TTI针对新数据不可用的条件下，设置传输状态以指示重新传输，以及重新传送与所标识的HARQ进程相关联的数据。

摘要： 本发明公开了一种Eu2+/Eu3+:Y1.8‑xLa0.2ZrxO3透明陶瓷及其制备方法，用少量ZrO2控制Eu2+/Eu3+:Y1.8La0.2O3透明陶瓷中Eu2+与Eu3+的比例，从而实现红光强度任意可调。根据检测实验证实，通过调节ZrO2掺杂浓度可实现红光发射强度在传统Eu3+:Y1.8La0.2O3透明陶瓷与Eu2+/Eu3+:Y1.8La0.2O3透明陶瓷之间任意变化，可满足现代照明与显示领域对不同发光强度的要求。由于ZrO2价格比Eu2O3低廉，比起传统通过改变Eu含量来调节发光强度，Eu2+/Eu3+:Y1.8‑xLa0.2ZrxO3透明陶瓷成本更低，可减少对稀土的需求量。

摘要： 本发明公开了一种Eu2+‑Eu3+共掺杂氟铝酸盐基质荧光粉，该荧光粉的分子式为：Ca12‑xAl14O32F2：xEu，其中0.2＜x＜0.6，该荧光粉的分子结构中的Eu是指Eu2+和Eu3+共存的混合物。本发明反应时间短，煅烧温度低，能耗小，通过改变合成条件和激发波长，可以调整蓝光发射和红光发射的强度比例，得到近似白光的光。

摘要： 一种Eu3+/Eu2+掺杂的铝酸盐多色荧光材料及制备方法，材料基质由CaCO3、Al2O3按摩尔比为1:1组成，掺入物Eu2O3、SiO2的摩尔分数分别为基质的2%、x%（x=25、50、200）；制备步骤包括：精确地按照配比称取原料，将原料混合均匀后持续研磨直至混合均匀；将研磨后的粉体装填至刚玉坩埚，放入马弗炉中在空气气氛中进行1000‑1300°C高温固相反应8‑20h，炉冷至900°C时取出冷却至室温，研磨均匀后即可得到样品。本发明制备工艺简单、成本低廉，无毒无污染，产物物化性能稳定；对实验设备尤其是其密封性的要求较低；安全性高，容易量产；Eu2+发射为宽带发射，发射峰强度及位置可调，紫外吸收良好。

摘要： 本发明公开了一种Eu2+、Eu3+离子共激活的光学温度传感材料的制备方法及所制备得到的荧光粉材料。该种光学温度传感材料的化学通式为Sr3.96Al14O25:0.04Eu2+/3+，采用的制备方法为高温固相法，即按照化学计量比将原料混合，在常压、空气气氛中、1400°C下保温烧结5小时，最后将烧结产物破碎处理后得到光学温度传感材料。本发明制备工艺简单，参数易于调控。所述材料可由紫外或近紫外光激发，激发光谱范围较宽，发射光谱包含主峰位于492nm的蓝色荧光和617nm的红色荧光，分别对应于Eu2+的4f65d‑4f7和Eu3+的5D0‑7FJ（J=1,2,4）跃迁。该种材料的绝对温度灵敏度可达0.015 K‑1，相对温度灵敏度可达1.1%K‑1，可以准确测量环境温度的变化，具有在非接触式光学温度传感领域的应用潜力。

摘要： 本发明公开了一种拓扑化学还原Eu3+/Eu2+共掺UV‑LED白光微晶玻璃及其制备方法，由如下摩尔百分比计的组份制得：40‑60％的SiO2、10‑25％的Al2O3、10‑20％的Na2CO3、8‑15％的YF3、6‑15％的NaF、0.1‑0.5％的Eu2O3和0.02‑0.1％的还原剂，所述还原剂为氮化物或碳化物，按设定配比，将各原料组份混合研磨，经熔融、退火制得所述的白光微晶玻璃。本发明直接在空气中高温固相熔融反应，利用氮化物或碳化物还原剂部分原位还原Eu3+从而实现Eu3+与Eu2+的共掺杂，在395nm紫外激发下产生白光，得到白光微晶玻璃。

摘要： 本发明公开一种Eu2+‑Eu3+共掺杂硅酸盐荧光粉及其制备方法和应用。化学通式为：KBaLuSi2O7:xmol％Eu，其中0.1≤x≤50，Eu是指Eu2+和Eu3+共存的混合物，其比值范围为其比值范围为0.02～20；通过调整Eu2+和Eu3+的掺杂浓度，实现从蓝绿光到白光调控。本发明以单斜晶相结构的硅酸盐KBaLuSi2O7为基质，以铕离子为激活剂，在还原气氛中通过调节铕离子的浓度，可以实现掺杂的铕离子从Eu2+到Eu2+‑Eu3+共存的转变，发射波段范围更宽，通过调整蓝绿光和红光发射的强度比例，得到趋于白光的光。

摘要： 本发明公开了一种Eu2+和Eu3+铕离子混合激活的荧光粉、制备方法及应用，属于发光材料技术领域。本发明提供的荧光粉其化学式为Na2‑2xEu2xAl2B4O10，其中x为铕离子掺杂摩尔数，0.001≤x≤0.07；它的基质为Na2Al2B4O10，激活剂是铕离子，是Eu2+和Eu3+共存的混合。本发明提供的荧光粉的制备采用化学溶胶‑凝胶法合成，烧结在空气气氛中进行。荧光粉在紫外和近紫外光的激发下，可以得到从蓝光到白光的不同发光颜色。本发明制备工艺简单，尤其是对于制备设备的密封性要求不高，生产安全性好，成本低廉、无污染排放，得到的荧光粉为多色发光，且颜色连续可调。